Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
【XinSheng Academic】PD-1 Combined with Anti-EGFR Monoclonal Antibody/Anti-Angiogenic Drug Re-challenges PD-1-Progressed Recurrent Metastatic Nasopharyngeal Carcinoma
View details
→
[Case Study] Issue 284: Nilotinib for the Treatment of Tonsillar Cancer
【XinSheng Academic】2023 SNO Conference Features Study on Nilotinib Treatment for Pediatric Gliomas
[Case Study] Issue 283: Nilotinib Treatment for Giant Cell Glioblastoma
Cuban Prime Minister Marrero leads delegation to visit BIOTECH PHARMACEUTICAL CO., LTD
[Shengxin Case] Issue 282: A Case Report on Nilotinib Treatment for Nasopharyngeal Carcinoma